Dietary SCFAs Immunotherapy: Reshaping the Gut Microbiota in Diabetes

Yu Anne Yap, Eliana Marino

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

7 Citations (Scopus)


Diet-microbiota related inflammatory conditions such as obesity, autoimmune type 1 diabetes (T1D), type 2 diabetes (T2D), cardiovascular disease (CVD) and gut infections have become a stigma in Western societies and developing nations. This book chapter examines the most relevant pre-clinical and clinical studies about diet-gut microbiota approaches as an alternative therapy for diabetes. We also discuss what we and others have extensively investigated- the power of dietary short-chain fatty acids (SCFAs) technology that naturally targets the gut microbiota as an alternative method to prevent and treat diabetes and its related complications.

Original languageEnglish
Title of host publicationDiabetes
Subtitle of host publicationfrom Research to Clinical Practice
EditorsMd. Shahidul Islam
Place of PublicationSwitzerland
Number of pages21
ISBN (Electronic)9783030510893
ISBN (Print)9783030510886
Publication statusPublished - 2021

Publication series

NameAdvances in Experimental Medicine and Biology
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019


  • Clinical trials
  • Diet
  • Microbiota
  • SCFAs
  • T1D
  • T2D

Cite this